Replies to post #199479 on Biotech Values

[linhdtu]

Er I remember reading praises for Axon CEO's ability to find values in the trash bin of pharma giants. That was about the time of the IPO when pps was sky high too. It is essential to remember these things to properly calibrate my perspective against the info du jour .lol

[kris_kade]

Even if RVT-101 shows any efficacy from 'sub-group' analysis, it will be a suspect IMO

[MinnieM]

AXON - Does anyone happen to have a link handy showing results of the ph II trial mentioned here?

http://axovant.com/clinical-trials/mindset-trial/

The MINDSET Phase 3 trial is designed to confirm the results of a 684-patient international, multi-center, double-blind placebo-controlled study in which patients on a stable background of donepezil therapy receiving 35 mg intepirdine demonstrated statistically significant improvements on the ADAS-cog and ADCS-ADL as compared to patients receiving donepezil alone.

I don't hold long or short, but, would like to understand the high valuation.